Atyr_Logo.png
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
November 30, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences in November
November 12, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
November 10, 2021 16:00 ET | aTyr Pharma, Inc.
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2...
Atyr_Logo.png
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 08:05 ET | aTyr Pharma, Inc.
 Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
Atyr_Logo.png
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
November 03, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Participate in Piper Sandler Investor Lung Day
October 11, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
October 06, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
October 01, 2021 08:01 ET | aTyr Pharma, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
researchdrivelogo.jpg
Global Organ Care System for Heart Market Anticipated to Garner a Revenue of $44.02 Million at a CAGR of 19.4% during the Forecast Period, 2019-2026 COVID-19 Disaster - Exclusive Report by Research Dive
September 21, 2021 09:30 ET | Research Dive
New York, USA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- According to a recent report by Research Dive, the global organ care system for heart market is forecasted to reach $44.02 million by the end of...
Atyr_Logo.png
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 20, 2021 16:07 ET | aTyr Pharma, Inc.
SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...